Martingale Asset Management L P Ironwood Pharmaceuticals Inc Transaction History

Martingale Asset Management L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$8.79 - $11.51 $1,230 - $1,611	-140 Reduced 0.1%	139,858 $1.6 Million
Q2 2023 Aug 11, 2023	BUY	$10.1 - $11.6 $57,630 - $66,189	5,706 Added 4.25%	139,998 $1.49 Million
Q1 2023 May 12, 2023	BUY	$10.37 - $12.56 $28,019 - $33,937	2,702 Added 2.05%	134,292 $1.41 Million
Q4 2022 Feb 13, 2023	BUY	$9.9 - $12.43 $28,086 - $35,263	2,837 Added 2.2%	131,590 $1.63 Million
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $37,548 - $45,843	3,703 Added 2.96%	128,753 $1.34 Million
Q2 2022 Aug 11, 2022	BUY	$11.05 - $12.72 $319,367 - $367,633	28,902 Added 30.06%	125,050 $1.44 Million
Q1 2022 May 12, 2022	BUY	$10.61 - $12.88 $1.02 Million - $1.24 Million	96,148 New	96,148 $1.21 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $562M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.